Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy IQVIA stock
Learn how to easily invest in IQVIA stock.
IQVIA Holdings Inc is a diagnostics & research business based in the US. IQVIA shares (IQV) are listed on the NYSE and all prices are listed in US Dollars. IQVIA employs 77,000 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in IQVIA
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IQV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
IQVIA stock price (NYSE: IQV)Use our graph to track the performance of IQV stocks over time.
IQVIA shares at a glance
|Latest market close||$240.95|
|52-week range||$170.00 - $285.61|
|50-day moving average||$264.60|
|200-day moving average||$248.56|
|Wall St. target price||$303.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$3.93|
Buy IQVIA shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy IQVIA stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
IQVIA price performance over time
|1 week (2022-01-14)||-2.58%|
|1 month (2021-12-22)||-12.94%|
|3 months (2021-10-22)||-6.20%|
|6 months (2021-07-22)||-1.62%|
|1 year (2021-01-22)||29.83%|
|2 years (2020-01-22)||50.12%|
|3 years (2019-01-22)||92.98%|
|5 years (2017-01-20)||216.62%|
Is IQVIA stock undervalued or overvalued?
Valuing IQVIA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IQVIA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IQVIA's P/E ratio
IQVIA's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 63x. In other words, IQVIA shares trade at around 63x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IQVIA's PEG ratio
IQVIA's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0379. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IQVIA's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IQVIA's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.3 billion.
The EBITDA is a measure of a IQVIA's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$13.5 billion|
|Operating margin TTM||9.33%|
|Gross profit TTM||$3.9 billion|
|Return on assets TTM||3.3%|
|Return on equity TTM||13.12%|
|Market capitalisation||$47.3 billion|
TTM: trailing 12 months
IQVIA's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IQVIA.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
IQVIA's total ESG risk score
Total ESG risk: 26.81
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IQVIA's overall score of 26.81 (as at 12/31/2018) is pretty good – landing it in it in the 37th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IQVIA is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
IQVIA's environmental score
Environmental score: 1.17/100
IQVIA's environmental score of 1.17 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
IQVIA's social score
Social score: 14.76/100
IQVIA's social score of 14.76 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
IQVIA's governance score
Governance score: 6.88/100
IQVIA's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that IQVIA is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
IQVIA's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. IQVIA scored a 1 out of 5 for controversy – the highest score possible, reflecting that IQVIA has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||26.81|
|Total ESG percentile||36.72|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||1|
IQVIA share dividends
We're not expecting IQVIA to pay a dividend over the next 12 months.
IQVIA share price volatility
Over the last 12 months, IQVIA's shares have ranged in value from as little as $170 up to $285.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IQVIA's is 1.4075. This would suggest that IQVIA's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
IQVIA in the news
Forte Capital Llc Buys AMN Healthcare Services Inc, IQVIA Holdings Inc, West Pharmaceutical ...
Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ...
Cooper Investors Remains Optimistic in IQVIA Holdings (IQV)
Frequently asked questionsWhat percentage of IQVIA is owned by insiders or institutions?
Currently 0.711% of IQVIA shares are held by insiders and 90.552% by institutions. How many people work for IQVIA?
Latest data suggests 77,000 work at IQVIA. When does the fiscal year end for IQVIA?
IQVIA's fiscal year ends in December. Where is IQVIA based?
IQVIA's address is: 4820 Emperor Blvd., Durham, NC, United States, 27703 What is IQVIA's ISIN number?
IQVIA's international securities identification number is: US46266C1053 What is IQVIA's CUSIP number?
IQVIA's Committee on Uniform Securities Identification Procedures number is: 46266C105
More guides on Finder
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Ask an Expert